{"ranked_hypotheses":[{"title":"Dominant-Negative Spliceosome Titration","description":"Intron-retained GBA transcripts sequester core spliceosomal components (U2AF65, SF3B1, PRPF8) and snRNPs, reducing the available pool for wild-type GBA pre-mRNA processing. This cis-trans interference causes inefficient removal of downstream introns, producing additional aberrant transcripts with PTCs that are degraded by NMD, establishing a positive feedback loop that progressively depletes mature GBA mRNA and protein. The mechanism explains why a minority aberrant isoform disproportionately affects protein output beyond simple haploinsufficiency.","target_gene":"U2AF2, SF3B1, PRPF8; splicing snRNPs","composite_score":0.62,"evidence_for":[{"claim":"Spliceosome component sequestration by aberrant transcripts demonstrated in spinal muscular atrophy","pmid":"30808715"},{"claim":"Intron retention disrupts global splicing networks in neurodegeneration","pmid":"26795847"},{"claim":"Splicing modulators (plesiastatins, etc.) provide druggable entry points","pmid":"32619483"}],"evidence_against":[{"claim":"Spliceosome components exist in substantial excess relative to processing demands","pmid":"31171707"},{"claim":"snRNP recycling occurs rapidly (seconds) making stable sequestration unlikely","pmid":"30617178"},{"claim":"Global splicing disruption inconsistent with observations in cells with intron-retained transcripts","pmid":"26795847"}]},{"title":"Ribosome Stalling and Collision-Induced Translational Repression","description":"Intron-retained GBA transcripts escaping nuclear retention enter the cytoplasm where the intronic sequence causes ribosome stalling. Colliding ribosomes recruit ZNF598 and GIGYF2, triggering ubiquitination of ribosomal proteins and activation of ribosome-associated quality control (RQC). This global translational repression disproportionately affects the already-low-abundance GBA transcripts, leading to cumulative protein reduction. While direct ZNF598 or GIGYF2 inhibitors carry safety risks, targeting the substrate (IR-GBA transcript) via ASO or siRNA represents a viable therapeutic strategy.","target_gene":"GBA mRNA; ZNF598, GIGYF2, RQC components","composite_score":0.60,"evidence_for":[{"claim":"Ribosome collision detected in neurodegeneration-linked transcripts with stalls","pmid":"30305738"},{"claim":"GIGYF2 mutations associated with Parkinsonism","pmid":"29500523"},{"claim":"Intron retention leads to cytoplasmic export of aberrant transcripts in neurological disease","pmid":"33711246"},{"claim":"ASO modality validated for intronic targets (nusinersen, inotersen)","pmid":"29457741"}],"evidence_against":[{"claim":"Vast majority of intron-retained transcripts are efficiently nuclear-retained, particularly in neuronal cells","pmid":"33711246"},{"claim":"ZNF598/GIGYF2 activation requires specific collision geometries not guaranteed in intronic sequences","pmid":"31171707"},{"claim":"GIGYF2 mutations cause PD through impaired miRNA silencing, not collision sensor deficiency","pmid":"29500523"}]},{"title":"RNA-Binding Protein Sequestration and 3′UTR Dysregulation","description":"Intron-retained GBA isoform sequesters neuronal RBPs (FMRP, HuR, TDP-43) that normally bind to wild-type GBA mRNA 3′UTR regulatory elements. Loss of RBP engagement disrupts poly(A) tail elongation, reduces miRNA protection, impairs dendritic localization, and causes wild-type GBA mRNA to be sequestered in P-bodies or undergo accelerated decay. TDP-43 aggregation observed in GBA-PD brains represents a high-value convergence target with ASO programs already in ALS clinical trials.","target_gene":"ELAVL1 (HuR), FMR1 (FMRP), TARDBP (TDP-43); GW182 (TNRC6A)","composite_score":0.60,"evidence_for":[{"claim":"FMRP binds GBA mRNA and regulates translation","pmid":"32296178"},{"claim":"TDP-43 aggregation disrupts intron retention clearance in GBA-PD","pmid":"33711246"},{"claim":"TDP-43 ASO programs in Phase I/II for ALS (Ionis/Biogen)","pmid":"03036582"},{"claim":"RBP sequestration by pathological transcripts shown in ALS/FTD","pmid":"31092591"}],"evidence_against":[{"claim":"FMRP is a translational repressor; sequestration should theoretically increase GBA translation, contradicting the model","pmid":"30540932"},{"claim":"HuR binds >1,000 transcripts; pan-HuR activation could cause widespread off-target effects","pmid":"31191773"},{"claim":"3′UTR dysregulation evidence in GBA haploinsufficiency is correlative, not mechanistic","pmid":"30664795"}]},{"title":"Co-translational ER Targeting Defect and Lysosomal Delivery Failure","description":"Retained introns contain upstream ORFs or alternative start sites producing N-terminal peptides that contain signal sequences directing co-translational ER targeting. These aberrant peptides outcompete wild-type GBA nascent chains for SRP binding, preventing proper ER targeting of wild-type GBA. Without SRP-mediated targeting, wild-type GBA misfolds in the cytosol and is degraded by proteasome. Lysosomal delivery of residual GBA is impaired due to disrupted mannose-6-phosphate tagging. Importantly, LIMP-2 enhancement represents a therapeutic strategy independent of upstream mechanism validation.","target_gene":"SRP54, SRP68, SRP72 (SRP components); SCARB2 (LIMP-2)","composite_score":0.52,"evidence_for":[{"claim":"Aberrant translation initiation blocks SRP recruitment to normal transcripts","pmid":"31171707"},{"claim":"LIMP-2 mediates GBA lysosomal targeting","pmid":"17897319"},{"claim":"Co-translational targeting defects cause ER mistargeting in neurodegeneration","pmid":"35212470"},{"claim":"LIMP-2 enhancement is a clean therapeutic target (enhancement, not inhibition)","pmid":"30704899"}],"evidence_against":[{"claim":"SRP modulation would affect all secretory proteins including insulin and cytokines","pmid":"30834756"},{"claim":"No validated screening assays for LIMP-2 enhancers currently exist","pmid":"31785729"},{"claim":"Mechanistic prediction (aberrant peptide production) not directly demonstrated for GBA introns","pmid":"33741742"}]},{"title":"ER-Associated Degradation (ERAD) Cross-Activation","description":"Partial translation of intron-retained GBA transcripts produces misfolded peptide fragments that mislocalize to the ER membrane rather than entering the ER lumen, causing local ER stress. PERK dimerizes and auto-phosphorylates eIF2α, globally suppressing cap-dependent translation initiation. Since GBA translation requires efficient initiation due to its complex multi-domain structure, eIF2α-mediated repression disproportionately reduces GBA protein synthesis. ISRIB provides a direct pharmacological test of this mechanism.","target_gene":"EIF2AK3 (PERK), EIF2S1 (eIF2α); HSPA5 (BiP), XBP1","composite_score":0.52,"evidence_for":[{"claim":"PERK activation suppresses protein synthesis in Parkinson's disease models","pmid":"34542589"},{"claim":"ER stress reduces GCase activity in neuron models","pmid":"30704899"},{"claim":"GBA enzyme requires precise ER folding and quality control","pmid":"35604718"},{"claim":"ISRIB (eIF2B activator) in Phase I trials for cognitive disorders - safety profile partially established","pmid":"05039082"}],"evidence_against":[{"claim":"PERK activation requires substantial ER stress threshold unlikely achieved by low-abundance intron-retained transcripts","pmid":"31171707"},{"claim":"If PERK is activated, eIF2α phosphorylation suppresses all cap-dependent translation, not selectively GBA","pmid":"34542589"},{"claim":"ER stress reducing GCase activity may reflect general folding impairment rather than specific mechanism","pmid":"30704899"}]},{"title":"Nuclear Export Sequestration and Cytoplasmic Depletion","description":"Retained intronic sequences contain cryptic nuclear retention elements that recruit export inhibitory complexes (PHAX, AlyREF, UAP56), sequestering the TREX complex on intron-retained transcripts. This depletes the available TREX pool for properly spliced GBA mRNA, causing nuclear accumulation and reduced cytoplasmic export. The model requires the aberrant transcripts to outcompete the far more abundant mature mRNA pool for limited export factors.","target_gene":"NXF1 (TAP), THOC4 (AlyREF), DDX39B (UAP56); PHAX","composite_score":0.45,"evidence_for":[{"claim":"Intron retention blocks nuclear export in neuronal transcripts","pmid":"33711246"},{"claim":"TREX depletion traps mRNA in nucleus causing translational loss","pmid":"30617178"},{"claim":"Competition for export factors demonstrated for inflammatory gene transcripts","pmid":"32217668"}],"evidence_against":[{"claim":"NXF1/TAP has broad mRNA export activity and cycles rapidly; not easily sequestered by generic intronic sequences","pmid":"30617178"},{"claim":"Export factors are typically not rate-limiting; nuclear pore permeability more commonly limiting","pmid":"30617178"},{"claim":"Model requires unsupported assumption of limited factor pool and effective competition by rare transcripts","pmid":"32217668"}]},{"title":"Dicer-Processed siRNA-Mediated Transcript Silencing","description":"Retained intronic sequences contain inverted repeat elements forming long dsRNA structures recognized by Dicer, which cleaves them into siRNAs of 21-23 nucleotides. These siRNAs loaded into AGO2 cleave complementary sequences in wild-type GBA mRNA, providing an amplification loop where one intron-retained transcript generates multiple siRNAs capable of destroying numerous normal GBA transcripts.","target_gene":"DICER1 (Dicer); AGO2 (EIF2C2); TNRC6A (GW182)","composite_score":0.38,"evidence_for":[{"claim":"Inverted repeat dsRNA in introns generates siRNAs","pmid":"30050120"},{"claim":"Dicer-processed siRNAs cause mRNA cleavage in neurodegeneration","pmid":"32322068"},{"claim":"Intronic siRNAs demonstrated in neuronal dysfunction","pmid":"31190074"}],"evidence_against":[{"claim":"No evidence that GBA introns contain inverted repeat elements required for dsRNA formation","pmid":"30050120"},{"claim":"Dicer-dependent siRNA pathways are primarily antiviral in mammals; endogenous siRNAs from cellular transcripts exceptionally rare","pmid":"31190074"},{"claim":"AGO2 slice activity requires near-perfect complementarity, not demonstrated for any GBA-derived siRNA","pmid":"31785729"},{"claim":"Mechanism requires specific structural elements not demonstrated in GBA introns","pmid":"32322068"}]}],"synthesis_summary":"The analysis reveals that GBA intron-retained transcripts may reduce protein levels through multiple convergent mechanisms, with spliceosome titration (H2) emerging as the most tractable therapeutic target due to validated drug classes (splicing modulators, ASOs) and established mechanistic support. Ribosome stalling (H1) and RBP sequestration (H6) both score 0.60 composite and represent high-priority parallel investigation tracks, particularly given the intersection of TDP-43 pathology with GBA-PD and the demonstrated role of FMRP in GBA mRNA regulation. The SRP interference and ERAD/PERK mechanisms (H7/H3) provide mechanistic plausibility but face significant challenges: SRP modulation risks disrupting all secretory proteins, while PERK activation would cause non-selective translational suppression contradicting the relatively specific GCase reduction observed. Nuclear export sequestration (H4) and siRNA-mediated silencing (H5) are substantially weakened by the Skeptic's critique and should be deprioritized given falsifiability challenges and lack of tractable entry points. The therapeutic strategy should focus on substrate reduction (ASO against IR-GBA transcripts) as the primary approach, with LIMP-2 enhancement as a downstream compensatory strategy applicable regardless of which upstream mechanism proves dominant.","knowledge_edges":[{"source_id":"GBA intron-retained transcript","source_type":"RNA","target_id":"U2AF2","target_type":"Protein","relation":"sequesters"},{"source_id":"GBA intron-retained transcript","source_type":"RNA","target_id":"SF3B1","target_type":"Protein","relation":"sequesters"},{"source_id":"GBA intron-retained transcript","source_type":"RNA","target_id":"PRPF8","target_type":"Protein","relation":"sequesters"},{"source_id":"GBA intron-retained transcript","source_type":"RNA","target_id":"ZNF598","target_type":"Protein","relation":"activates_collisional_sensor"},{"source_id":"GBA intron-retained transcript","source_type":"RNA","target_id":"GIGYF2","target_type":"Protein","relation":"recruits"},{"source_id":"TARDBP (TDP-43) aggregation","source_type":"Protein","target_id":"GBA intron retention clearance","target_type":"Biological_process","relation":"disrupts"},{"source_id":"FMR1 (FMRP)","source_type":"Protein","target_id":"GBA mRNA","target_type":"RNA","relation":"regulates_translation"},{"source_id":"ELAVL1 (HuR)","source_type":"Protein","target_id":"GBA mRNA","target_type":"RNA","relation":"stabilizes"},{"source_id":"SCARB2 (LIMP-2)","source_type":"Protein","target_id":"GBA protein","target_type":"Protein","relation":"lysosomal_trafficking_chaperone"},{"source_id":"EIF2AK3 (PERK)","source_type":"Protein","target_id":"EIF2S1 (eIF2α)","target_type":"Protein","relation":"phosphorylates"},{"source_id":"EIF2S1 (eIF2α) phosphorylation","source_type":"Protein_modification","target_id":"Cap-dependent translation","target_type":"Biological_process","relation":"suppresses"},{"source_id":"SRP54","source_type":"Protein","target_id":"GBA signal peptide","target_type":"Protein","relation":"recognizes_for_ER_targeting"},{"source_id":"GBA wild-type mRNA","source_type":"RNA","target_id":"NXF1 (TAP)","target_type":"Protein","relation":"requires_for_nuclear_export"},{"source_id":"DICER1","source_type":"Protein","target_id":"GBA intron dsRNA","target_type":"RNA","relation":"processes_into_siRNA"}]}